GlassScriptPhysician profile
David Lynn Stotts
NPI 1629565551
$5,574.40
in general payments reported to CMS, 2019-2025
45 companies · $2,075 in 2025
The $2,075 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $463 · 2023: $1,875 · 2024: $1,161 · 2025: $2,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,111.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,294.38 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Corium, LLC | $447.21 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $389.30 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $382.91 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $352.91 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $302.94 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.77 | 2022-2025 | Jardiance |
| Inspire Medical Systems, INC. | $228.55 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $190.03 | 2022-2024 | Breztri, Farxiga, Airsupra |
| Axsome Therapeutics, INC. | $182.79 | 2023-2025 | Auvelity, Symbravo, Sunosi |
| Nevro Corp. | $130.24 | 2023-2024 | Senza |
| Pfizer INC. | $124.11 | 2023-2025 | |
| Dexcom, INC. | $122.95 | 2023-2025 | Dexcom G6 Transmitter |
| Avvisto Therapeutics, LLC | $107.15 | 2025 | Cycloset |
| Abbott Laboratories | $93.07 | 2024-2025 | Freestyle Libre |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stotts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.